Loading
Panbela Therapeutics
Panbela Therapeutics is a Minnesota biotech whose drug ivospemin starves pancreatic cancer of polyamines, molecules the tumour needs to grow, and is being tested with gemcitabine and nab-paclitaxel in first-line treatment.
Also called: Sun BioPharmaNASDAQ:PBLA
Overview
Panbela Therapeutics, formerly Sun BioPharma, develops polyamine-targeting therapies. Ivospemin (SBP-101) is a polyamine analogue that is taken up preferentially by pancreatic acinar and cancer cells and disrupts polyamine metabolism. The phase 2/3 ASPIRE trial tested ivospemin with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. Through its acquisition of Cancer Prevention Pharmaceuticals it also holds eflornithine-based programmes for familial adenomatous polyposis.
Headquarters
Waconia, Minnesota, US
Scorecard
All companies#450of 1245 companies, score 7
- phase 3 +3
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:PBLA
Stage
Public
Website
Products
1Phase 3small molecule
Ivospemin is an experimental small-molecule drug from Panbela Therapeutics in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.
Connected
2drugs
Phase 3small molecule
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
panbela.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Link 193 company-less drugs to their makers and add 74 ma… · diff · file
Sourced, not expert-reviewed